Background: The conquest and colonization of Venezuela generated very heterogeneous populations as a product of admixture; for this reason, the distribution of polymorphisms of the CYP2C19 gene was studied in various Venezuelan populations.
Methods: Two hundred and eighty-one individuals, from three Venezuelan populations with different admixtures, were genotyped for CYP2C19*2 and CYP2C19*3 polymorphisms. Differences between groups were analysed using a chi-square test of heterogeneity and association of allele frequencies with the level of genetic admixture was performed using a principal component analysis (PCA). No significant differences in distribution of alleles, genotypes and phenotypes were found between the populations studied.
Results: In Venezuela, high frequencies of the alleles CYP2C19*2 and CYP2C19*3 were found compared with Europeans, Africans and Latin Americans, similar to those reported in Asia. PCA analysis suggested that the presence of alleles CYP2C19*2 and CYP2C19*3 is associated with the indigenous component in the Venezuelan populations studied.
Conclusions: Future studies are needed to confirm this association. High frequencies of intermediate metabolizers (20-38%) and of poor metabolizers (2-7%) were observed, similar to values reported for Asians and higher than those reported for South Americans. This is the first study evaluating CYP2C19 polymorphisms in the Venezuelan general population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/03014460.2012.749946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Implementation of a Genotype-Guided P2Y Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients.
JACC Cardiovasc Interv
July 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Cardiology, University Medical Center Maastricht, Maastricht, the Netherlands.
Article Synopsis
- The study investigated whether using CYP2C19 genetic testing to guide medication choices improves outcomes for patients with acute coronary syndrome (ACS) compared to standard treatment.
- Out of 5,321 ACS patients, those who were genotyped and had their medications tailored showed significantly lower bleeding rates while maintaining a similar risk of ischemic events compared to those on standard therapy.
- The findings suggest that a personalized approach to antiplatelet therapy based on genetic markers can enhance safety without compromising efficacy in managing ACS.
Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals.
Indian Heart J
November 2023
Center of Excellence in Molecular Biology and Regenerative Medicine, Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, India; Special Interest Group - Human Genomics and Rare Disorders, JSS Academy of Higher Education & Research, Mysuru, India. Electronic address:
Article Synopsis
- This study investigates the prevalence of CYP2C19 alleles, focusing on loss-of-function (LoF) alleles (CYP2C19∗2, CYP2C19∗3) and gain-of-function (GoF) alleles (CYP2C19∗17) in a population of 300 healthy adults.
- Researchers used allele-specific PCR to determine the frequencies of these alleles and the resulting metabolic phenotypes (ultra-rapid, extensive, intermediate, and poor metabolizers).
- Results showed a high frequency of poor metabolizers (12.67%) and recommended pre-treatment genotype testing to tailor drug dosages and reduce adverse effects.
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Genet Res (Camb)
November 2022
Department of Cardiology, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, China.
Objective: Clopidogrel is widely used for preventing ischemic complications related to cardiovascular diseases. However, many patients experience clopidogrel resistance (CR). The polymorphisms of CYP2C19 have been implicated in CR, but CYP2C19 polymorphism considerably varies with both ethnic group and geographical location.
View Article and Find Full Text PDFIncidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention.
Indian Heart J
June 2021
Sree Balaji Medical College Hospital, Chromepet, Chennai, 600044, India.
Article Synopsis
- The study aimed to determine the incidence of major adverse cardiovascular events (MACE) in patients undergoing percutaneous coronary intervention (PCI) using genotype-guided antiplatelet therapy.
- Researchers analyzed salivary samples from patients to identify variations in the CYP2C19 gene, classifying them into normal, intermediate, or poor metabolizers before prescribing antiplatelet medication.
- Findings showed that the majority of patients were intermediate metabolizers and only a small percentage experienced MACE within six months, suggesting that genotype testing can effectively tailor treatment and reduce complications post-PCI.
CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression.
Heliyon
May 2020
Department of Pharmacology, Laboratory of Biochemistry and Molecular Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Article Synopsis
- Escitalopram (ESC) is a medication used to treat depression and anxiety, predominantly metabolized by the enzyme CYP2C19, which varies among individuals due to genetic differences.
- A study involving 31 patients with major depressive disorder (MDD) found that different CYP2C19 genetic profiles affected how these patients responded to ESC, with ultrarapid metabolizers needing higher doses for treatment.
- The findings suggest that patients with the CYP2C19 ultrarapid metabolizer phenotype may require higher doses or combination therapy to achieve remission from MDD, highlighting the importance of genetic factors in antidepressant treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!